This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A few years back, TIGIT was hailed as the ...

Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or ...

That was fast. Just 39 hours after the bombshell failure of Roche’s TIGIT trial, iTeos Therapeutics revealed it and GlaxoSmithKline are assessing “how best to proceed with additional clinical ...

At the 2025 European Society of Medical Oncology (ESMO) Congress 2025, held from17 to 21 October in Berlin, Germany, results from the Phase III IMbrave152/SKYSCRAPER-14 study were presented. The study ...

After announcing a phase 3 launch based on positive midstage results, iTeos Therapeutics and GSK are finally sharing the highlights from the phase 2 TIGIT trial, revealing a more than 30% difference ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Chimeric antigen receptor (CAR) T Cell therapy has emerged as a promising immunotherapeutic approach to treat blood cancers, even leading to long-lasting remission for some advanced cases. The FDA has ...

In 2020, immuno-oncology was at an inflection point. The first wave of PD1 blockers had shown that immune checkpoint inhibitors could be transformative for some cancer patients. But next-generation ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. This is the online edition of ESMO in 30 Seconds, a pop-up newsletter ...

GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments. It’s the latest ...